Physician profile
Anna C Loomis
NPI 1992734370
$3,238.60
in general payments reported to CMS, 2019-2025
26 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.63 · 2021: $25.96 · 2022: $191 · 2023: $1,320 · 2024: $1,321 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.71 | 2022-2025 | |
| Pfizer INC. | $379.70 | 2022-2025 | |
| Novo Nordisk INC | $326.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $261.59 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $250.49 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $250.02 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.40 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $169.54 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Biogen, INC. | $115.26 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $105.95 | 2023-2025 | Veozah |
| Amgen INC. | $100.18 | 2019-2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $97.58 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $71.34 | 2023-2024 | Belsomra, Capvaxive, Gardasil 9 |
| Stryker Corporation | $66.26 | 2025 | Clottriever Bold Catheter |
| Dexcom, INC. | $37.32 | 2023-2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.48 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $31.79 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $23.27 | 2022 | |
| Exeltis, USA INC. | $22.68 | 2024 | Slynd |
| Daiichi Sankyo INC. | $21.64 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.24 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.53 | 2024 | Voquezna |
| Lundbeck LLC | $15.81 | 2023 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2023 | |
| Neos Therapeutics, LP | $14.09 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Loomis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.